Cargando…
Role of autoantibodies and blood–brain barrier leakage in cognitive impairment in systemic lupus erythematosus
OBJECTIVE: Cognitive impairment is common in patients with SLE but the cause is unknown. The current cross-sectional study examined the association between select SLE-related autoantibodies, other serological biomarkers and extensive blood–brain barrier (BBB) leakage in patients with SLE with and wi...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204449/ https://www.ncbi.nlm.nih.gov/pubmed/35705307 http://dx.doi.org/10.1136/lupus-2022-000668 |
_version_ | 1784728929761755136 |
---|---|
author | Hanly, John G Legge, Alexandra Kamintsky, Lyna Friedman, Alon Hashmi, Javeria A Beyea, Steven D Fisk, John Omisade, Antonina Calkin, Cynthia Bardouille, Tim Bowen, Chris Matheson, Kara Fritzler, Marvin J |
author_facet | Hanly, John G Legge, Alexandra Kamintsky, Lyna Friedman, Alon Hashmi, Javeria A Beyea, Steven D Fisk, John Omisade, Antonina Calkin, Cynthia Bardouille, Tim Bowen, Chris Matheson, Kara Fritzler, Marvin J |
author_sort | Hanly, John G |
collection | PubMed |
description | OBJECTIVE: Cognitive impairment is common in patients with SLE but the cause is unknown. The current cross-sectional study examined the association between select SLE-related autoantibodies, other serological biomarkers and extensive blood–brain barrier (BBB) leakage in patients with SLE with and without cognitive impairment. In addition, we determined whether the relationship between SLE autoantibodies, other biomarkers and cognitive impairment differed depending on the presence or absence of concurrent extensive BBB leakage. METHODS: Consecutive patients with SLE, recruited from a single academic medical centre, underwent formal neuropsychological testing for assessment of cognitive function. On the same day, BBB permeability was determined using dynamic contrast-enhanced MRI scanning. SLE autoantibodies and other serological biomarkers were measured. Regression modelling was used to determine the association between cognitive impairment, extensive BBB leakage and autoantibodies/biomarkers. RESULTS: There were 102 patients with SLE; 90% were female and 88% were Caucasian, with a mean±SD age of 48.9±13.8 years. The mean±SD SLE disease duration was 14.8±11.0 years. Impairment in one or more cognitive tests was present in 47 of 101 (47%) patients and included deficits in information processing speed (9%), attention span (21%), new learning (8%), delayed recall (15%) and executive abilities (21%). Extensive BBB leakage was present in 20 of 79 (25%) patients and was associated with cognitive impairment (15 of 20 (75%) vs 24 of 59 (41%); p=0.01) and shorter disease duration (median (IQR): 7 (8–24 years) vs 15 (2–16 years); p=0.02). No serological parameters were associated with extensive BBB leakage and there was no statistically significant association between cognitive impairment and circulating autoantibodies even after adjusting for BBB leakage. CONCLUSIONS: Extensive BBB leakage alone was associated with cognitive impairment. These findings suggest that BBB leakage is an important contributor to cognitive impairment, regardless of circulating SLE-related autoantibodies. |
format | Online Article Text |
id | pubmed-9204449 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-92044492022-06-29 Role of autoantibodies and blood–brain barrier leakage in cognitive impairment in systemic lupus erythematosus Hanly, John G Legge, Alexandra Kamintsky, Lyna Friedman, Alon Hashmi, Javeria A Beyea, Steven D Fisk, John Omisade, Antonina Calkin, Cynthia Bardouille, Tim Bowen, Chris Matheson, Kara Fritzler, Marvin J Lupus Sci Med Immunology and Inflammation OBJECTIVE: Cognitive impairment is common in patients with SLE but the cause is unknown. The current cross-sectional study examined the association between select SLE-related autoantibodies, other serological biomarkers and extensive blood–brain barrier (BBB) leakage in patients with SLE with and without cognitive impairment. In addition, we determined whether the relationship between SLE autoantibodies, other biomarkers and cognitive impairment differed depending on the presence or absence of concurrent extensive BBB leakage. METHODS: Consecutive patients with SLE, recruited from a single academic medical centre, underwent formal neuropsychological testing for assessment of cognitive function. On the same day, BBB permeability was determined using dynamic contrast-enhanced MRI scanning. SLE autoantibodies and other serological biomarkers were measured. Regression modelling was used to determine the association between cognitive impairment, extensive BBB leakage and autoantibodies/biomarkers. RESULTS: There were 102 patients with SLE; 90% were female and 88% were Caucasian, with a mean±SD age of 48.9±13.8 years. The mean±SD SLE disease duration was 14.8±11.0 years. Impairment in one or more cognitive tests was present in 47 of 101 (47%) patients and included deficits in information processing speed (9%), attention span (21%), new learning (8%), delayed recall (15%) and executive abilities (21%). Extensive BBB leakage was present in 20 of 79 (25%) patients and was associated with cognitive impairment (15 of 20 (75%) vs 24 of 59 (41%); p=0.01) and shorter disease duration (median (IQR): 7 (8–24 years) vs 15 (2–16 years); p=0.02). No serological parameters were associated with extensive BBB leakage and there was no statistically significant association between cognitive impairment and circulating autoantibodies even after adjusting for BBB leakage. CONCLUSIONS: Extensive BBB leakage alone was associated with cognitive impairment. These findings suggest that BBB leakage is an important contributor to cognitive impairment, regardless of circulating SLE-related autoantibodies. BMJ Publishing Group 2022-06-15 /pmc/articles/PMC9204449/ /pubmed/35705307 http://dx.doi.org/10.1136/lupus-2022-000668 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Immunology and Inflammation Hanly, John G Legge, Alexandra Kamintsky, Lyna Friedman, Alon Hashmi, Javeria A Beyea, Steven D Fisk, John Omisade, Antonina Calkin, Cynthia Bardouille, Tim Bowen, Chris Matheson, Kara Fritzler, Marvin J Role of autoantibodies and blood–brain barrier leakage in cognitive impairment in systemic lupus erythematosus |
title | Role of autoantibodies and blood–brain barrier leakage in cognitive impairment in systemic lupus erythematosus |
title_full | Role of autoantibodies and blood–brain barrier leakage in cognitive impairment in systemic lupus erythematosus |
title_fullStr | Role of autoantibodies and blood–brain barrier leakage in cognitive impairment in systemic lupus erythematosus |
title_full_unstemmed | Role of autoantibodies and blood–brain barrier leakage in cognitive impairment in systemic lupus erythematosus |
title_short | Role of autoantibodies and blood–brain barrier leakage in cognitive impairment in systemic lupus erythematosus |
title_sort | role of autoantibodies and blood–brain barrier leakage in cognitive impairment in systemic lupus erythematosus |
topic | Immunology and Inflammation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204449/ https://www.ncbi.nlm.nih.gov/pubmed/35705307 http://dx.doi.org/10.1136/lupus-2022-000668 |
work_keys_str_mv | AT hanlyjohng roleofautoantibodiesandbloodbrainbarrierleakageincognitiveimpairmentinsystemiclupuserythematosus AT leggealexandra roleofautoantibodiesandbloodbrainbarrierleakageincognitiveimpairmentinsystemiclupuserythematosus AT kamintskylyna roleofautoantibodiesandbloodbrainbarrierleakageincognitiveimpairmentinsystemiclupuserythematosus AT friedmanalon roleofautoantibodiesandbloodbrainbarrierleakageincognitiveimpairmentinsystemiclupuserythematosus AT hashmijaveriaa roleofautoantibodiesandbloodbrainbarrierleakageincognitiveimpairmentinsystemiclupuserythematosus AT beyeastevend roleofautoantibodiesandbloodbrainbarrierleakageincognitiveimpairmentinsystemiclupuserythematosus AT fiskjohn roleofautoantibodiesandbloodbrainbarrierleakageincognitiveimpairmentinsystemiclupuserythematosus AT omisadeantonina roleofautoantibodiesandbloodbrainbarrierleakageincognitiveimpairmentinsystemiclupuserythematosus AT calkincynthia roleofautoantibodiesandbloodbrainbarrierleakageincognitiveimpairmentinsystemiclupuserythematosus AT bardouilletim roleofautoantibodiesandbloodbrainbarrierleakageincognitiveimpairmentinsystemiclupuserythematosus AT bowenchris roleofautoantibodiesandbloodbrainbarrierleakageincognitiveimpairmentinsystemiclupuserythematosus AT mathesonkara roleofautoantibodiesandbloodbrainbarrierleakageincognitiveimpairmentinsystemiclupuserythematosus AT fritzlermarvinj roleofautoantibodiesandbloodbrainbarrierleakageincognitiveimpairmentinsystemiclupuserythematosus |